Overview

Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer

Status:
Completed
Trial end date:
2016-08-18
Target enrollment:
0
Participant gender:
All
Summary
This phase I/II trial studies the side effects and best dose of sirolimus when given together with cisplatin and gemcitabine hydrochloride and to see how well they work in treating patients with bladder cancer. Biological therapies, such as sirolimus, may stimulate or suppress the immune system in different ways and stop tumor cells from growing. Drugs used in chemotherapy, such as cisplatin and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving sirolimus together with cisplatin and gemcitabine hydrochloride may be an effective treatment for bladder cancer.
Phase:
Phase 1/Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University of Washington
Collaborator:
National Cancer Institute (NCI)
Treatments:
Cisplatin
Everolimus
Gemcitabine
Sirolimus
Succinylcholine
Criteria
Inclusion Criteria:

- Signed informed consent form (ICF) providing agreement to adhere to the dosing
schedule, report for all trial visits and authorization, use and release of health and
research trial information

- Histologically or cytologically confirmed carcinoma of the bladder of all histologies
except neuroendocrine differentiation or squamous cell histology

- Eastern Cooperative Oncology Group (ECOG) performance status of =< 1

- Eligibility for phase 1 and phase 2 components:

- Phase 1 - clinical T3 or T4 or N1 or M1 cancer which is untreated or previously
treated with platinum based therapy with primary tumor still present in the
bladder and amenable to sampling before and after treatment, as indicated

- Phase 2 - clinical T2-4 N0 or N1 untreated with primary tumor still present in
the bladder and amenable to sampling before and after treatment, as indicated

- Life expectancy >= 12 weeks

- No prior malignancy is allowed except:

- Adequately treated basal cell or squamous cell skin cancer or

- In situ carcinoma of any site or

- Other adequately treated malignancy for which the patient is currently disease
free for at least one year

- Absolute neutrophil count >= 1.5 x 10^9 cells/L

- Hemoglobin (Hgb) >= 9.0 g/dL

- Platelets >= 100,000 x 10^9/L

- Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 1.5 x upper limit
of normal (ULN)

- Bilirubin and total bilirubin levels =< 1.5 x ULN

- Serum creatinine < 1.5 X institutional ULN mg/dL OR glomerular filtration rate (GFR)
>= 50 mL/min

- All pre-study labs required for determination of eligibility are to be completed
within 30 days prior to day -2 (or the next business day if falls on a weekend or
holiday)

- X-rays and/or scans to assess all disease sites are to be completed within 30 days
prior to day -2 (or the next business day if falls on a weekend or holiday)

Exclusion Criteria:

- Patients currently receiving active therapy for other neoplastic disorders

- Known parenchymal brain metastasis

- Active or symptomatic viral hepatitis or chronic liver disease

- Clinically significant heart disease as evidenced by myocardial infarction, or
arterial thrombotic events in the past 6 months, severe or unstable angina, or New
York Heart Association (NYHA) class II-IV heart disease or cardiac ejection fraction
measurement of < 45 % at baseline, if done

- Atrial fibrillation, or other cardiac arrhythmia requiring medical therapy

- Administration of an investigational therapeutic within 30 days of cycle 1, day 1

- Patients with dementia/psychiatric illness/social situations that would limit
compliance with study requirements or would prohibit the understanding and/or giving
of informed consent

- Patients with medical conditions, which, in the opinion of the investigators, would
jeopardize either the patient or the integrity of the data obtained will not be
eligible

- Any condition which, in the opinion of the investigator, would preclude participation
in this trial